499 related articles for article (PubMed ID: 23880740)
1. Timing and outcomes for radical cystectomy in nonmuscle invasive bladder cancer.
Zehnder P; Thalmann GN
Curr Opin Urol; 2013 Sep; 23(5):423-8. PubMed ID: 23880740
[TBL] [Abstract][Full Text] [Related]
2. [Radical cystectomy in patients with non-muscle invasive bladder cancer who fail BCG therapy].
Huguet J; Gaya JM; Sabaté S; Palou J; Villavicencio H
Actas Urol Esp; 2010 Jan; 34(1):63-70. PubMed ID: 20223134
[TBL] [Abstract][Full Text] [Related]
3. Survival rates after radical cystectomy according to tumor stage of bladder carcinoma at first presentation.
May M; Helke C; Nitzke T; Vogler H; Hoschke B
Urol Int; 2004; 72(2):103-11. PubMed ID: 14963349
[TBL] [Abstract][Full Text] [Related]
4. Optimal timing of radical cystectomy for patients with T1 bladder cancer.
Bochner BH
Urol Oncol; 2009; 27(3):329-31. PubMed ID: 19414124
[TBL] [Abstract][Full Text] [Related]
5. Role of immediate radical cystectomy in the treatment of patients with residual T1 bladder cancer on restaging transurethral resection.
Sternberg IA; Keren Paz GE; Chen LY; Herr HW; Dalbagni G
BJU Int; 2013 Jul; 112(1):54-9. PubMed ID: 23146082
[TBL] [Abstract][Full Text] [Related]
6. Incidence and location of lymph node metastases in patients undergoing radical cystectomy for clinical non-muscle invasive bladder cancer: results from a prospective lymph node mapping study.
Bruins HM; Skinner EC; Dorin RP; Ahmadi H; Djaladat H; Miranda G; Cai J; Daneshmand S
Urol Oncol; 2014 Jan; 32(1):24.e13-9. PubMed ID: 23395238
[TBL] [Abstract][Full Text] [Related]
7. Non-muscle invasive high grade urothelial carcinoma of the bladder. Which factors can influence understaging at the time of radical cystectomy?
Minardi D; Milanese G; Parri G; Lacetera V; Muzzonigro G
Arch Ital Urol Androl; 2016 Mar; 88(1):13-6. PubMed ID: 27072170
[TBL] [Abstract][Full Text] [Related]
8. Oncological outcome of primary versus secondary muscle-invasive bladder cancer is comparable after radical cystectomy.
Aziz A; Gierth M; Fritsche HM; May M; Otto W; Denzinger S; Wieland WF; Merseburger A; Riedmiller H; Kocot A; Burger M
Urol Int; 2013; 91(1):97-102. PubMed ID: 23751372
[TBL] [Abstract][Full Text] [Related]
9. Can re-cTURBT be useful in pT1HG disease as a risk indicator of recurrence and progression? A single centre experience.
Giulianelli R; Gentile BC; Mirabile G; Albanesi L; Tariciotti P; Rizzo G; Buscarini M; Vermiglio M
Arch Ital Urol Androl; 2017 Dec; 89(4):272-276. PubMed ID: 29473376
[TBL] [Abstract][Full Text] [Related]
10. Lymphovascular invasion of urothelial cancer in matched transurethral bladder tumor resection and radical cystectomy specimens.
Kunju LP; You L; Zhang Y; Daignault S; Montie JE; Lee CT
J Urol; 2008 Nov; 180(5):1928-32; discussion 1932. PubMed ID: 18801529
[TBL] [Abstract][Full Text] [Related]
11. Cystectomy in patients with high risk superficial bladder tumors who fail intravesical BCG therapy: pre-cystectomy prostate involvement as a prognostic factor.
Huguet J; Crego M; Sabaté S; Salvador J; Palou J; Villavicencio H
Eur Urol; 2005 Jul; 48(1):53-9; discussion 59. PubMed ID: 15967252
[TBL] [Abstract][Full Text] [Related]
12. [Prostatic involvement by urothelial carcinoma in patients with bladder cancer and their implications in the clinical practice].
Huguet J
Actas Urol Esp; 2012 Oct; 36(9):545-53. PubMed ID: 22520044
[TBL] [Abstract][Full Text] [Related]
13. Female gender and carcinoma in situ in the prostatic urethra are prognostic factors for recurrence, progression, and disease-specific mortality in T1G3 bladder cancer patients treated with bacillus Calmette-Guérin.
Palou J; Sylvester RJ; Faba OR; Parada R; Peña JA; Algaba F; Villavicencio H
Eur Urol; 2012 Jul; 62(1):118-25. PubMed ID: 22101115
[TBL] [Abstract][Full Text] [Related]
14. Restaging transurethral resection for non-muscle invasive bladder cancer: who, why, when, and how?
Ritch CR; Clark PE; Morgan TM
Urol Clin North Am; 2013 May; 40(2):295-304. PubMed ID: 23540786
[TBL] [Abstract][Full Text] [Related]
15. Lymphadenectomy in bladder cancer: how high is "high enough"?
Stein JP
Urol Oncol; 2006; 24(4):349-55. PubMed ID: 16818190
[TBL] [Abstract][Full Text] [Related]
16. Radical cystectomy with an extended pelvic lymphadenectomy: rationale and results.
Mills RD; Fleischmann A; Studer UE
Surg Oncol Clin N Am; 2007 Jan; 16(1):233-45. PubMed ID: 17336246
[TBL] [Abstract][Full Text] [Related]
17. Selective bladder preservation with curative intent for muscle-invasive bladder cancer: a contemporary review.
Koga F; Kihara K
Int J Urol; 2012 May; 19(5):388-401. PubMed ID: 22409269
[TBL] [Abstract][Full Text] [Related]
18. Prospective Assessment of Vesical Imaging Reporting and Data System (VI-RADS) and Its Clinical Impact on the Management of High-risk Non-muscle-invasive Bladder Cancer Patients Candidate for Repeated Transurethral Resection.
Del Giudice F; Barchetti G; De Berardinis E; Pecoraro M; Salvo V; Simone G; Sciarra A; Leonardo C; Gallucci M; Catalano C; Catto JWF; Panebianco V
Eur Urol; 2020 Jan; 77(1):101-109. PubMed ID: 31699526
[TBL] [Abstract][Full Text] [Related]
19. The optimum timing of radical cystectomy for patients with recurrent high-risk superficial bladder tumour.
Solsona E; Iborra I; Rubio J; Casanova J; Almenar S
BJU Int; 2004 Dec; 94(9):1258-62. PubMed ID: 15610101
[TBL] [Abstract][Full Text] [Related]
20. Invasive T1 bladder cancer: indications and rationale for radical cystectomy.
Stein JP; Penson DF
BJU Int; 2008 Aug; 102(3):270-5. PubMed ID: 18494831
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
